Do symptomatic asthmatic smokers need a higher maintenance dose when treated with budesonide/formoterol maintenance and reliever therapy than non-smokers?

O. C. P. van Schayck, M. Aubier, R. Buhl, J. Ostinelli, T. Ekström, L. Jörgensen, J. Haughney (Netherlands; Paris, Rueil-Malmaison, France; , Germany; Södertälje, Sweden; Aberdeen, United Kingdom)

Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Session: Combination therapy in asthma and COPD
Session type: Thematic Poster Session
Number: 1198
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. C. P. van Schayck, M. Aubier, R. Buhl, J. Ostinelli, T. Ekström, L. Jörgensen, J. Haughney (Netherlands; Paris, Rueil-Malmaison, France; , Germany; Södertälje, Sweden; Aberdeen, United Kingdom). Do symptomatic asthmatic smokers need a higher maintenance dose when treated with budesonide/formoterol maintenance and reliever therapy than non-smokers?. Eur Respir J 2010; 36: Suppl. 54, 1198

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017
Year: 2018



Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 616s
Year: 2007

Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007


Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009

Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Variation of regular maintenance therapy with budesonide/formoterol of children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007


Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008

Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002

Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004